Journal
BREAST CANCER RESEARCH
Volume 23, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13058-021-01480-1
Keywords
Breast cancer recurrence; Hypoxia-inducible factor 1; Tamoxifen resistance; Prognostic marker
Categories
Funding
- US NCI [R21CA185932]
- NCI [R01CA118708, R01CA166825, F31CA239566]
- Danish Cancer Society [DP06117]
- Lundbeck Foundation [R1672013-15861]
- Danish Medical Research Council [DOK 1158869]
- Karen Elise Jensen Foundation
- Glenn Family Breast Center at the Winship Cancer Institute
- National Center for Advancing Translational Sciences of the National Institutes of Health [TL1TR002540]
Ask authors/readers for more resources
The study found that HIF-1α expression is not directly associated with overall breast cancer recurrence, but may be related to early recurrence in patients with ER-negative breast cancer.
Background Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a transcription factor that facilitates the adaptation of cancer cells to hypoxic conditions and may be prognostic of breast cancer recurrence. We evaluated the association of HIF-1 alpha expression with breast cancer recurrence, and its association with timing of breast cancer recurrence. Methods In this population-based case-control study, we included women diagnosed with stage I-III breast cancer between 1985 and 2001, aged 35-69 years, registered in the Danish Breast Cancer Group. We identified 541 cases of breast cancer recurrence among women with estrogen receptor (ER)-positive disease who were treated with tamoxifen for at least 1 year (ER+ TAM+). We also enrolled 300 breast cancer recurrence cases among women with ER-negative disease, not treated with tamoxifen, who survived at least 1 year (ER-/TAM-). Controls were recurrence-free breast cancer patients at the time of case diagnosis, matched to recurrence cases on ER/TAM status, date of surgery, menopausal status, cancer stage, and county of residence. Expression of HIF-1 alpha was measured by immunohistochemistry on tissue microarrays. We fitted logistic regression models to compute odds ratios (ORs) and 95% confidence intervals (CIs) associating HIF-1 alpha expression with recurrence, and with timing of recurrence. Results HIF-1 alpha expression was observed in 23% of cases and 20% of controls in the ER+/TAM+ stratum, and in 47% of cases and 48% of controls in the ER-/TAM- stratum. We observed a near-null association between HIF-1 alpha expression in both ER/TAM groups (ER+/TAM+ OR = 1.21, 95%CI 0.88, 1.67 and ER-/TAM- OR = 0.97, 95%CI 0.68, 1.39). HIF-1 alpha expression was not associated with time to recurrence among women in the ER+/TAM+ stratum, but was associated with early recurrence among women in the ER-/TAM- stratum. Conclusion In this study, HIF-1 alpha expression was not associated with breast cancer recurrence overall but may be associated with early recurrence among women diagnosed with ER- breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available